Calamos Advisors LLC grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 42,452 shares of the pharmaceutical company’s stock after buying an additional 3,681 shares during the quarter. Calamos Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $7,192,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also recently made changes to their positions in VRTX. Next Capital Management LLC lifted its holdings in shares of Vertex Pharmaceuticals by 84.4% during the 2nd quarter. Next Capital Management LLC now owns 166 shares of the pharmaceutical company’s stock valued at $30,000 after buying an additional 76 shares during the last quarter. Evolution Wealth Advisors LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter valued at about $32,000. Patriot Financial Group Insurance Agency LLC lifted its holdings in shares of Vertex Pharmaceuticals by 118.5% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 177 shares of the pharmaceutical company’s stock valued at $32,000 after buying an additional 96 shares during the last quarter. HM Payson & Co. acquired a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter valued at about $35,000. Finally, Captrust Financial Advisors lifted its holdings in shares of Vertex Pharmaceuticals by 204.1% during the 2nd quarter. Captrust Financial Advisors now owns 222 shares of the pharmaceutical company’s stock valued at $41,000 after buying an additional 149 shares during the last quarter. Institutional investors and hedge funds own 94.79% of the company’s stock.
Several research firms recently weighed in on VRTX. Bank of America began coverage on Vertex Pharmaceuticals in a report on Wednesday, October 16th. They issued a “buy” rating and a $220.00 target price for the company. ValuEngine lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, September 10th. Royal Bank of Canada set a $213.00 target price on Vertex Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 12th. Morgan Stanley boosted their target price on Vertex Pharmaceuticals from $215.00 to $240.00 and gave the stock an “overweight” rating in a report on Friday, September 6th. Finally, JPMorgan Chase & Co. restated a “buy” rating and issued a $212.00 target price on shares of Vertex Pharmaceuticals in a report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and fifteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $213.74.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Wednesday, July 31st. The pharmaceutical company reported $0.99 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.24. The company had revenue of $941.29 million for the quarter, compared to the consensus estimate of $884.66 million. Vertex Pharmaceuticals had a return on equity of 21.73% and a net margin of 64.13%. The company’s revenue for the quarter was up 25.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.94 EPS. Sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 3.42 earnings per share for the current fiscal year.
Vertex Pharmaceuticals announced that its board has initiated a share repurchase plan on Wednesday, July 31st that permits the company to buyback $500.00 million in outstanding shares. This buyback authorization permits the pharmaceutical company to purchase up to 1.2% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s management believes its stock is undervalued.
In other Vertex Pharmaceuticals news, EVP Stuart A. Arbuckle sold 2,155 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $177.78, for a total value of $383,115.90. Following the transaction, the executive vice president now directly owns 34,395 shares of the company’s stock, valued at approximately $6,114,743.10. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Sangeeta N. Bhatia sold 8,379 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $166.80, for a total value of $1,397,617.20. Following the completion of the transaction, the director now directly owns 7,810 shares in the company, valued at $1,302,708. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 44,053 shares of company stock worth $7,912,908. Company insiders own 0.70% of the company’s stock.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
Further Reading: Lock-Up Period Expiration
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.